Core Viewpoint - 港通医疗 is a specialized provider of medical engineering solutions in China, focusing on medical gas systems and clean operating rooms, and was listed on the Shenzhen Stock Exchange on July 25, 2023 [1] Business Overview - 港通医疗 operates in the pharmaceutical and biomedical industry, specifically in medical devices and equipment, providing comprehensive engineering solutions centered on medical gas systems and clean operating rooms [1] Financial Performance - For Q3 2025, 港通医疗 reported revenue of 344 million yuan, ranking 28th among 42 companies in the industry, while the industry leader,迈瑞医疗, had revenue of 25.834 billion yuan [2] - The net profit for the same period was -11.8366 million yuan, placing the company 35th in the industry, with the top performer, 迈瑞医疗, reporting a net profit of 7.814 billion yuan [2] Financial Ratios - As of Q3 2025, 港通医疗's debt-to-asset ratio was 40.94%, higher than the previous year's 31.69% and above the industry average of 27.21%, indicating increased debt pressure [3] - The gross profit margin for Q3 2025 was 22.45%, an increase from 20.02% year-on-year, but still significantly below the industry average of 48.67%, suggesting a need for improved profitability [3] Executive Compensation - The chairman, 陈永, received a salary of 627,200 yuan in 2024, a decrease of 242,100 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.11% to 7,506, while the average number of circulating A-shares held per shareholder increased by 1.12% to 8,398.82 [5]
港通医疗的前世今生：2025年Q3营收行业28，负债率高于行业、毛利率低于同业